Skip to content

Study · Non-randomized trial · n = 56 · 2010

4 results

Growth hormone response to GH-releasing peptide-2 in children.

Asakura Y, Toyota Y, Muroya K, Adachi M

Journal of pediatric endocrinology & metabolism : JPEM1 May 2010Cited by 7 (Europe PMC)

PMID20662346 (opens in a new tab)DOI10.1515/jpem.2010.078 (opens in a new tab)PepBankPUB-20662346
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialOther

    In 56 children with growth disorders, peak GH after GHRP‑2 correlated favourably with peak GH after the insulin tolerance test (P<0.0001).

    In plain wordsIn children with growth disorders, the GH peak after GHRP‑2 matched the GH peak after the insulin tolerance test.

    Peptide
    GHRP-2
    Outcome
    Not applicableCorrelation of GHRP-2 peak GH with ITT peak GH
    Study

    n = 56

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    The Spearman correlation coefficient for GH peak values indicated a favorable correlation with the ITT (P<0.0001).
    2 context sentences
    Summary · context
    We evaluated the GH response to GHRP-2 in 56 children with growth disorders to assess its efficacy.
    Summary · context
    A dose of 2 microg/kg of GHRP-2 was administered intravenously and serum GH concentrations were determined.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with growth hormone deficiency, peak GH after GHRP‑2 was lower than in children without it (median 3.39 versus 25.10 microg/l, p<0.0001).

    In plain wordsChildren with growth hormone deficiency had a lower GH peak after GHRP‑2 than children without it.

    Peptide
    GHRP-2
    Outcome
    DecreasePeak GH after GHRP-2 in children with versus without GHD
    Study

    n = 56

    Comparator
    Children without GHD
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg/kg · intravenousAs given in this study (human).

    Measurements

    Peak GH (median)
    3.39 microg/l
    children with GHD
    Peak GH (median)
    25.1 microg/l
    children without GHD

    Source sentences

    Summary
    Peak GH concentrations were significantly (p<0.0001) lower in children with (median: 3.39 microg/l (ng/ml)) than without (25.10 microg/l (ng/ml)) GHD.
    2 context sentences
    Summary · context
    We evaluated the GH response to GHRP-2 in 56 children with growth disorders to assess its efficacy.
    Summary · context
    A dose of 2 microg/kg of GHRP-2 was administered intravenously and serum GH concentrations were determined.
  3. 03HumanNon-randomized trialOther

    In the sensitivity-specificity analysis, sensitivity crossed specificity at a serum GH concentration of 15 microg/l after GHRP‑2.

    In plain wordsThe GH level at which the GHRP‑2 test balanced sensitivity and specificity for diagnosing deficiency in children was 15 microg/l.

    Peptide
    GHRP-2
    Outcome
    Not applicableDiagnostic cut-off of GH peak after GHRP-2
    Study

    n = 56

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg/kg · intravenousAs given in this study (human).

    Measurements

    GH cut-off
    15 microg/l
    sensitivity equals specificity

    Source sentences

    Summary
    In the analysis of sensitivity-specificity curves, the serum concentration at the point where sensitivity crosses specificity was 15 microg/l (ng/ml).
    2 context sentences
    Summary · context
    We evaluated the GH response to GHRP-2 in 56 children with growth disorders to assess its efficacy.
    Summary · context
    A dose of 2 microg/kg of GHRP-2 was administered intravenously and serum GH concentrations were determined.
  4. 04HumanNon-randomized trialSafety outcome

    In children with growth disorders, the GHRP‑2 test was reported as safe; the abstract gives no adverse event counts.

    In plain wordsThe GHRP‑2 test was reported as safe in children, but the abstract gives no event numbers.

    Peptide
    GHRP-2
    Outcome
    No significant changeSafety of the GHRP-2 test
    Study

    n = 56

    Outcome group
    Adverse events · Whole body
    Studied dose
    2 microg/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    The GHRP-2 test was safe and required only one hour or less, and was capable of diagnosing GHD in children.
    2 context sentences
    Summary · context
    We evaluated the GH response to GHRP-2 in 56 children with growth disorders to assess its efficacy.
    Summary · context
    A dose of 2 microg/kg of GHRP-2 was administered intravenously and serum GH concentrations were determined.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.